Carolin Barth

Carolin Barth is a seasoned global healthcare executive with a diverse background encompassing over 15 years of experience in the pharmaceutical and biotechnology industry.

She has held various leadership roles with a focus on commercial and development functions, demonstrating a wide range of capabilities across different geographies, particularly in the US and EU.

Carolin boasts extensive knowledge in product development, including the successful launch of 4 biologics, specialty medicine, and cell therapies.

Her professional track record highlights a strong aptitude for team building and fostering high-performing, collaborative teams.

With a medical degree and a background in strategic consulting, Carolin Barth brings a unique blend of medical expertise and business acumen to her roles.

Her specialties include pipeline strategy, global product launch, marketing and sales strategy and operations, digital medicine, biologics, cell and gene therapies, hematology and oncology, autoimmune disease, dermatology, and ophthalmology.

Carolin Barth studied Medicine at the University of Tübingen, obtaining an MD and Dr. med. degree.

She currently serves as the Chief Executive Officer at MiroBio Ltd, and has previously held key positions such as Global Head Commercial & Pipeline Strategy, Cell & Gene at Novartis Oncology.

Carolin's prior roles at Novartis include Global Program Head for Chronic Myeloid Leukemia (CML), Rheumatology, Dermatology, Autoimmune Diseases, and Rheumatology.

Additionally, she has experience as the Global Head of Dermatology and New Products - Integrated Hospital Care at Novartis, and has held positions in brand leadership, sales, and as a Junior Engagement Manager at McKinsey & Company.

In her early career, Carolin Barth worked as a Resident in Hematology & Oncology at University Hospital Tübingen, further enriching her extensive professional journey.